Edelweiss Pharma Analytic Acta (ISSN: 2689-9477)
Editor
Biography
Dr. Alain L Fymat is a
medical-physical scientist and an educator. He is the current President/CEO and
Professor at the International Institute of Medicine and Science with a
previous appointment as Executive Vice President, Chief Operating Officer and
Professor at the Weil Institute of Critical Care Medicine. He was educated at
the University of Paris-Sorbonne and the University of California at Los Angeles.
He was formerly Professor of Radiology, Radiological Sciences, Radiation
Medicine (Oncology), Critical Care Medicine, and Physics at several U.S. and
European Universities. Previously, he was Deputy Director (Western Region) of
the U.S. Department of Veterans Affairs, Veterans Health Administration (Office
of Research Oversight), and Director of the Magnetic Resonance Imaging Center
and for a time Acting Chair of Radiology at its Loma Linda, California Medical
Center. He has extensively published (~ 425 publications including patents,
books & monographs, book chapters, refereed articles). As invited/keynote
speaker and member of organizing committees of international congresses and
symposia, he has lectured extensively across the USA, Canada, Europe, Africa
and Asia. He has been the recipient of numerous research grants from
government, academia and private industry, and has consulted extensively with
these entities. He is a Board member of several institutions and Health Advisor
of the American Heart & Stroke Association (Coachella Valley Division,
California). He is Editor-in-Chief, Honorable Editor or Editor of 35
medical-scientific Journals. He published more than 37 articles in different
journals.
Research Interest
Nanomedicine, nanobiotechnology, cancer/oncology, molecular/personal/precision medicine, human genetics/ epigenetics/ ecogenetics, neurodegenerative diseases, and pharmacogenomics. His most recent publications deal with nanotechnology and cancer, nanochemotherapy, nanoneurology, natural and synthetic immunotherapy, drug delivery across the brain protective barriers, and neurodegenerative disorders (epilepsy, Parkinson and Alzheimer diseases)
